Galida Uses, Dosage, Side Effects and more

Galida is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Galida is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.

Treatment with tesaglitazar lowered fasting plasma glucose, improved glucose tolerance, substantially reduced fasting and postload insulin levels, and markedly lowered fasting TG and improved lipid tolerance.

Trade Name Galida
Generic Tesaglitazar
Tesaglitazar Other Names Tesaglitazar
Type
Formula C20H24O7S
Weight Average: 408.465
Monoisotopic: 408.124273812
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Uses

Investigated for use/treatment in diabetes mellitus type 2.

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.
Share